ArticleProceedings of the National Academy of Sciences of the United States of America1996
Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 208 citations in OpenAlex.
- Efficacy of T-Cell Receptor-Based Adoptive Cell Therapy in Cutaneous Melanoma: A Meta-Analysis.The oncologist · 2023Pooled it
- A universal platform for simultaneous TCRα/β removal enables safer and more potent TCR therapies and autoimmune modeling.bioRxiv : the preprint server for biology · 2026Article
- Melan-A expression in non-melanocytic carcinoma: A potential diagnostic pitfall.Histology and histopathology · 2024Article
- Article
- MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial.Immuno-oncology technology · 2022Article
- Canine and feline uveal melanocytic tumours: Histologic and immunohistochemical characteristics of 32 cases.Veterinary medicine and science · 2022Article
- The Whitening Properties of the Mixture Composed of Pomegranate, Osmanthus and Olive and the Protective Effects Against Ultraviolet Deleterious Effects.Clinical, cosmetic and investigational dermatology · 2021Article
- Adoptive cellular therapies: the current landscape.Virchows Archiv : an international journal of pathology · 2019Review
- Rational Combination of Parvovirus H1 With CTLA-4 and PD-1 Checkpoint Inhibitors Dampens the Tumor Induced Immune Silencing.Frontiers in oncology · 2019Article
- Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma.Journal of oncology · 2019Review
- CD200 facilitates the isolation of corneal epithelial cells derived from human pluripotent stem cells.Scientific reports · 2018Article
- Protein Expression Analysis of Melanocyte Differentiation Antigen TRP-2.The American Journal of dermatopathology · 2016Article
- The Response of microRNAs to Solar UVR in Skin-Resident Melanocytes Differs between Melanoma Patients and Healthy Persons.PloS one · 2016Article
- Prospects for gene-engineered T cell immunotherapy for solid cancers.Nature medicine · 2016Article
- Article
- Specific roles of each TCR hemichain in generating functional chain-centric TCR.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- Investigation of cAMP microdomains as a path to novel cancer diagnostics.Biochimica et biophysica acta · 2014Review
- Adenovirus expressing β2-microglobulin recovers HLA class I expression and antitumor immunity by increasing T-cell recognition.Cancer gene therapy · 2014Article
- Diagnostic and prognostic biomarkers in melanoma.The Journal of clinical and aesthetic dermatology · 2014Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent progress in the structural identification of human melanoma antigens recognized by autologous cytotoxic T cells has led to the recognition of a new melanocyte differentiation antigen, Melan-A(MART-1). To determine the properties of the Melan-A gene product, Melan-A recombinant protein was produced in Escherichia coli and used to generate mouse monoclonal antibodies (mAbs). Two prototype mAbs, A103 and A355, were selected for detailed study. Immunoblotting results with A103 showed a 20-22-kDa doublet In Melan-A mRNA positive melanoma cell lines and no reactivity with Melan-A mRNA-negative cell lines. A355, in addition to the 20-22-kDa doublet, recognized several other protein species in Melan-A mRNA-positive cell lines. Immunocytochemical assays on cultured melanoma cells showed specific and uniform cytoplasmic staining in Melan-A mRNA-positive cell lines. Immunohistochemical analysis of normal human tissues with both mAbs showed staining of adult melanocytes and no reactivity with the other normal tissues tested. Analysis of 21 melanoma specimens showed homogenous staining of tumor cell cytoplasm in 16 of 17 Melan-A mRNA-positive cases and no reactivity with the three Melan-A mRNA-negative cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.